A phase 3 confrimatory study of ATL-962

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080220634

Enrollment

210

Registered

2008-11-20

Start date

2008-11-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Interventions

investigational material(s) Generic name etc : ATL-962 INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigatio

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Key Criteria for inclusion: The subject whose BMI is not less than 25 at the start and the end of the run-in period. The subject whose visceral fat area is not less than 100 cm2 at 8 weeks after the start of the run-in period(-4 Week). The subject who is diagnosed as type 2 diabetes mellitus and the HbA1C values are >= 6.5% and = 140 mg/dL Hypo-HDL cholesterolemia:HDL cholesterol = 150 mg/dL

Exclusion criteria

Exclusion criteria: Key Criteria for exclusion: The subject who have received any anti-obesity drugs (Mazindol and/or prescribed herb medicines which are indicated as an anti-obesity drug) within 4 weeks prior to the start of the run-in period

Design outcomes

Primary

Measure	Time frame
Body weight change at the completion of treatment from baseline	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026